Earning (Loss) Per Share

9 Months Ended

Sep. 30, 2023

Earnings Per Share [Abstract]

Earning (Loss) Per Share

Note 3 – Earning (Loss) Per Share

The earnings (loss) per share accounting guidance is discussed in Note 1. Diluted loss per share excludes all dilutive potential shares if their effect is anti-dilutive. The following table sets forth the computation of the Company’s basic and diluted net earnings (loss) per share available to common stockholders (unaudited) for the three and nine months ended September 30, 2023 and 2022:

	Three Months Ended September 30,						Nine Months Ended September 30,
	2023			2022			2023			2022
Numerator
Net income (loss) from continuing operations	$	(547,113	)	$	(1,339,865	)	$	1,544,377		$	(4,105,838	)
Deemed dividends		-			-			-			(330,876,369	)
Net income (loss) available to common stockholders, continuing operations		(547,113	)		(1,339,865	)		1,544,377			(334,982,207	)
Net loss from discontinued operations		(1,116	)		(1,696	)		(9,213	)		(7,075	)
Net income (loss) available to common stockholders	$	(548,229	)	$	(1,341,561	)	$	1,535,164		$	(334,989,282	)
Denominator
Weighted average number of shares of common stock outstanding during the period - basic		31,401,420,083			10,569,572,256			30,369,571,341			4,130,876,898
Warrants		-			-			20,977,778,506			-
Convertible preferred stock		-			-			451,710,162,027			-
Weighted average number of shares of common stock outstanding during the period - diluted		31,401,420,083			10,569,572,256			503,057,511,874			4,130,876,898
Net income (loss) per share of common stock available to common stockholders - basic:
Continuing operations	$	(0.00	)	$	(0.00	)	$	0.00		$	(0.08	)
Discontinued operations		(0.00	)		(0.00	)		(0.00	)		(0.00	)
Total basic	$	(0.00	)	$	(0.00	)	$	0.00		$	(0.08	)
Net income (loss) per share of common stock available to common stockholders - diluted:
Continuing operations	$	(0.00	)	$	(0.00	)	$	0.00		$	(0.08	)
Discontinued operations		(0.00	)		(0.00	)		(0.00	)		(0.00	)
Total diluted	$	(0.00	)	$	(0.00	)	$	0.00		$	(0.08	)

For the three months ended September 30, 2023 and 2022, the following potential common stock equivalents were excluded from the calculation of diluted loss per share as their effect was anti-dilutive:

	Three Months September 30,
	2023		2022
Warrants		511,333,351,089		511,333,351,092
Convertible preferred stock		444,750,633,333		466,707,633,333
Convertible debentures		28,777,833,333		28,777,833,333
Stock options		26		26
		984,861,817,781		1,006,818,817,784

For the nine months ended September 30, 2023 and 2022, the following potential common stock equivalents were excluded from the calculation of diluted loss per share as their effect was anti-dilutive:

	Nine Months September 30,
	2023		2022
Warrants		490,355,572,583		511,333,351,092
Convertible preferred stock		-		466,707,633,333
Convertible debentures		28,777,833,333		28,777,833,333
Stock options		26		26
		519,133,405,942		1,006,818,817,784

The terms of certain of the warrants, convertible preferred stock and convertible debentures issued by the Company provide for reductions in the per share exercise prices of the warrants and the per share conversion prices of the debentures and preferred stock (if applicable and subject to floors in certain cases) in the event that the Company issues common stock or common stock equivalents (as that term is defined in the agreements) at an effective exercise/conversion price that is less than the then exercise/conversion prices of the outstanding warrants, preferred stock or debentures, as the case may be. In addition, many of these securities contain exercise or conversion prices that vary based upon the price of the Company’s common stock on the date of exercise/conversion (see Notes 6, 9 and 10). These provisions have resulted in significant dilution of the Company’s common stock.

As a result of the Voting Agreement and Irrevocable Proxy (the “Voting Agreement”) discussed in Note 10 and the November 5, 2021 Amendment to the Company’s Certificate of Incorporation, as amended, to provide that the number of authorized shares of the Company’s common stock or preferred stock may be increased or decreased (but not below the number of shares then outstanding) by the affirmative vote of the holders of a majority in voting power of the stock of the Company, which is more fully discussed in Note 1, as of the date of filing this report, the Company believes that it has the ability to ensure that it has and/or can obtain sufficient authorized shares of its common stock to cover all outstanding rights to acquire potentially dilutive common shares.

As a result of these down round provisions, the potential common stock and common stock equivalents totaled 1.0 trillion at November 6, 2023. See Note 10 for a discussion of the number of shares of the Company’s authorized common and preferred stock.